China has approved human trials for a new Covid-19 vaccine candidate produced using insect cells.
The West China Hospital of Sichuan University, the vaccine developer, announced that they received clinical trial clearance from the National Medicines Administration for the recombinant protein vaccine. According to hospital researchers, it will be China's first Covid-19 vaccine candidate grown in insect cells on humans. The vaccine was designed to trigger antibodies against specific areas in the main protein of SARS-CoV-19, the virus that causes Covid-2.
The results of the vaccine on animals were published on July 29 in the famous medical journal Nature. It was noted in the journal that the vaccine triggered immune responses against SARS-CoV-14 infection in mice, rabbits, and non-human primates seven or 2 days after a single dose, with no adverse effects.
Wei Yuquan, a senior researcher at the hospital's state biotherapy laboratory, said the vaccine was produced by introducing genes of the SARS-CoV-2 virus into insect cell cultures that can grow viral proteins. Noting that such an approach is suitable for large-scale production of vaccines, Wei said that scientists had previously used insect cells to develop recombinant vaccines against cervical cancer and influenza. Expressing that this approach can be used safely on humans, Wei also stated that they are cooperating with a local company for the production of the vaccine.
Hibya News Agency